Nuclear factor-kappa B (NF-кB) comprises a family of protein transcription factors that have a regulatory function in numerous cellular processes and are implicated in the cancer cell response to antineoplastic drugs, including cisplatin. We characterized the effects of DNA adducts of cisplatin and ineffective transplatin on the affinity of NF-кB proteins to their consensus DNA sequence (кB site). Although the кB site-NF-κB protein interaction was significantly perturbed by DNA adducts of cisplatin, transplatin adducts were markedly less effective both in cell-free media and in cellulo using a decoy strategy derivatized-approach. Moreover, NF-κB inhibitor JSH-23 [4-methyl-N¹-(3-phenylpropyl)benzene-1,2-diamine] augmented cisplatin cytotoxicity in ovarian cancer cells and the data showed strong synergy with JSH-23 for cisplatin. The distinctive structural features of DNA adducts of the two platinum complexes suggest a unique role for conformational distortions induced in DNA by the adducts of cisplatin with respect to inhibition of the binding of NF-кB to the platinated кB sites. Because thousands of κB sites are present in the DNA, the mechanisms underlying the antitumor efficiency of cisplatin in some tumor cells may involve downstream processes after inhibition of the binding of NF-κB to κB site(s) by DNA adducts of cisplatin, including enhanced programmed cell death in response to drug treatment.

Centre de Biophysique Moléculaire CNRS Orléans France

Department of Biophysics Centre of the Region Hana for Biotechnological and Agricultural Research Faculty of Science Palacky University in Olomouc Czech Republic

Institute of Biophysics Academy of Sciences of the Czech Republic Brno Czech Republic

See more in PubMed

Ghosh S & Karin M (2002) Missing pieces in the NF-kappa B puzzle. Cell 109, S81-S96.

Pomerantz JL & Baltimore D (2002) Two pathways to NF-kappa B. Mol Cell 10, 693-695.

Ravi R & Bedi A (2004) NF-κB in cancer - a friend turned foe. Drug Resist Updates 7, 53-67.

Campbell KJ & Perkins ND (2006) Regulation of NF-kappa B function. Transcription, pp. 165-180. Portland Press Ltd, London.

Hayden MS & Ghosh S (2004) Signaling to NF-kappa B. Genes Dev 18, 2195-2224.

Verma IM, Stevenson JK, Schwarz EM, Vanantwerp D & Miyamoto S (1995) Rel/NF-κ-B/I-κ-B family: intimate tales of association and dissociation. Genes Dev 9, 2723-2735.

Baeuerle PA & Henkel T (1994) Function and activation of NF-κB in the immune system. Annu Rev Immunol 12, 141-179.

Thanos D & Maniatis T (1995) NF-κB: A lesson in family values. Cell 80, 529-532.

Karin M & Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 18, 621-663.

Hayden MS & Ghosh S (2012) NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 26, 203-234.

Smale ST (2011) Hierarchies of NF-κB target-gene regulation. Nature Immunol 12, 689-694.

Chen FE, Huang DB, Chen YQ & Ghosh G (1998) Crystal structure of p50/p65 heterodimer of transcription factor NF-kappa B bound to DNA. Nature 391, 410-413.

Huang D-B, Phelps CB, Fusco AJ & Ghosh G (2005) Crystal structure of a free κB DNA: insights into DNA recognition by transcription factor NF-κB. J Mol Biol 346, 147-160.

Schreiber J, Jenner RG, Murray HL, Gerber GK, Gifford DK & Young RA (2006) Coordinated binding of NF-κB family members in the response of human cells to lipopolysaccharide. Proc Natl Acad Sci USA 103, 5899-5904.

Martone R, Euskirchen G, Bertone P, Hartman S, Royce TE, Luscombe NM, Rinn JL, Nelson FK, Miller P, Gerstein M et al. (2003) Distribution of NF-κB-binding sites across human chromosome 22. Proc Natl Acad Sci USA 100, 12247-12252.

Natoli G, Saccani S, Bosisio D & Marazzi I (2005) Interactions of NF-κB with chromatin: the art of being at the right place at the right time. Nat Immunol 6, 439-445.

Wan F, Anderson DE, Barnitz RA, Snow A, Bidere N, Zheng L, Hegde V, Lam LT, Staudt LM, Levens D et al. (2007) Ribosomal protein S3: a KH domain subunit in NF-κB complexes that mediates selective gene regulation. Cell 131, 927-939.

Chen L-F & Greene WC (2004) Shaping the nuclear action of NF-κB. Nat Rev Mol Cell Biol 5, 392-401.

Wan F & Lenardo MJ (2009) Specification of DNA binding activity of NF-κB proteins. Cold Spring Harb Perspect Biol 1, a000067.

Huxford T, Malek S & Ghosh G (1999) Structure and mechanism in NF-κB/IκB signaling. Cold Spring Harb Symp Quant Biol 64, 533-540.

Luo J-L, Kamata H & Karin M (2005) The anti-death machinery in IKK/NF-kappa B signaling. J Clin Immunol 25, 541-550.

Dutta J, Fan Y, Gupta N, Fan G & Gelinas C (2006) Current insights into the regulation of programmed cell death by NF-kappa B. Oncogene 25, 6800-6816.

Nakanishi C & Toi M (2005) Nuclear factor-kappa B inhibitors as sensitizers to anticancer drugs. Nature Rev Cancer 5, 297-309.

Baud V & Karin M (2009) Is NF-kappa B a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8, 33-40.

Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P, Van Leer D, Leister W, Austin CP & Xia M (2010) Identification of known drugs that act as inhibitors of NF-κB signaling and their mechanism of action. Biochem Pharmacol 79, 1272-1280.

Sanchez-Perez I, Benitah SA, Martinez-Gomariz M, Lacal JC & Perona R (2002) Cell stress and MEKK1-mediated c-Jun activation modulate NF kappa B activity and cell viability. Mol Biol Cell 13, 2933-2945.

Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Saito M, Kawagoe J, Takahashi K, Yada-Hashimoto N et al. (2004) Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 279, 23477-23485.

Venkatraman M, Anto RJ, Nair A, Varghese M & Karunagaran D (2005) Biological and chemical inhibitors of NF-κB sensitize SiHa cells to cisplatin-induced apoptosis. Mol Carcinog 44, 51-59.

Strozyk E, Poppelmann B, Schwarz T & Kulms D (2006) Differential effects of NF-kappa B on apoptosis induced by DNA-damaging agents: the type of DNA damage determines the final outcome. Oncogene 25, 6239-6251.

Dhandapani KM, Mahesh VB & Brann DW (2007) Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NF kappa B transcription factors. J Neurochem 102, 522-538.

Solomon LA, Ali S, Banerjee S, Munkarah AR, Morris RT & Sarkar FH (2008) Sensitization of ovarian cancer cells to cisplatin by genistein: the role of NF-kappaB. J Ovarian Res 1, 9.

Chanvorachote P, Pongrakhananon V, Wannachaiyasit S, Luanpitpong S, Rojanasakul Y & Nimmannit U (2009) Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation. Cancer Invest 27, 624-635.

Oiso S, Ikeda R, Nakamura K, Takeda Y, Akiyama SI & Kariyazono H (2012) Involvement of NF-kappa B activation in the cisplatin resistance of human epidermoid carcinoma KCP-4 cells. Oncol Rep 28, 27-32.

Brabec V (2002) DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog Nucleic Acid Res Mol Biol 71, 1-68.

Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nature Rev Cancer 7, 573-584.

Fuertes MA, Castilla J, Alonso C & Perez JM (2003) Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem 10, 257-266.

Jung Y & Lippard SJ (2007) Direct cellular responses to platinum-induced DNA damage. Chem Rev 107, 1387-1407.

Pahl HL (1999) Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18, 6853-6866.

Sathe SS, Sizemore N, Li X, Vithalani K, Commane M, Swiatkowski SM & Stark GR (2004) Mutant human cells with constitutive activation of NF-κB. Proc Natl Acad Sci USA 101, 192-197.

Mann MJ & Dzau VJ (2000) Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest 106, 1071-1075.

Osako MK, Tomita N, Nakagami H, Kunugiza Y, Yoshino M, Yuyama K, Tomita T, Yoshikawa H, Ogihara T & Morishita R (2007) Increase in nuclease resistance and incorporation of NF-κB decoy oligodeoxynucleotides by modification of the 3′-terminus. J Gene Med 9, 812-819.

Sun X, Zhang J, Wang L & Tian Z (2008) Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett 262, 201-213.

Gao HH, Xiao JN, Sun Q, Lin HX, Bai YL, Yang L, Yang BF, Wang HZ & Wang ZG (2006) A single decoy oligodeoxynucleotides targeting multiple oncoproteins produces strong anticancer effects. Mol Pharmacol 70, 1621-1629.

Kisova A, Zerzankova L, Habtemariam A, Sadler PJ, Brabec V & Kasparkova J (2011) Differences in the cellular response and signaling pathways between cisplatin and monodentate organometallic Ru(II) antitumor complexes containing a terphenyl ligand. Mol Pharmaceutics 8, 949-957.

Yu L & Wang Z (2004) Difference in expression of Bcl-2 and Bcl-xl genes in cisplatin-sensitive and cisplatin-resistant human in ovarian cancer cell lines. J Huazhong Univ Sci Technol Med Sci 24, 151-153.

Shin HM, Kim MH, Kim BH, Jung SH, Kim YS, Park HJ, Hong JT, Kyung RM & Kim Y (2004) Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappa B without affecting I kappa B degradation. FEBS Lett 571, 50-54.

Kumar A, Negi G & Sharma SS (2011) JSH-23 targets nuclear factor-kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence. Diabetes Obesity Metab 13, 750-758.

Chou T-C & Talalay P (1983) Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4, 450-454.

Chou TC & Talalay P (1984) Quantitative-analysis of dose-effect relationships - the combined effects of multiple-drugs or enzyme-inhibitors. Adv Enzyme Regul 22, 27-55.

Muller CW, Rey FA, Sodeoka M, Verdine GL & Harrison SC (1995) Structure of the NF-κB p50 homodimer bound to DNA. Nature 373, 311-317.

Ghosh G, Vanduyne G, Ghosh S & Sigler PB (1995) Structure of NF-κB P50 homodimer bound to a κB site. Nature 373, 303-310.

Muller CW, Rey FA & Harrison SC (1996) Comparison of two different DNA-binding modes of the NF-kappa B p50 homodimer. Nature Struct Biol 3, 224-227.

Cramer P, Larson CJ, Verdine GL & Muller CW (1997) Structure of the human NF-kappa B p52 homodimer-DNA complex at 2.1 angstrom resolution. EMBO J 16, 7078-7090.

Yang DZ, van Boom SSGE, Reedijk J, van Boom JH & Wang AHJ (1995) Structure and isomerization of an intrastrand cisplatin-cross-linked octamer DNA duplex by NMR analysis. Biochemistry 34, 12912-12920.

Gelasco A & Lippard SJ (1998) NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) adduct d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin. Biochemistry 37, 9230-9239.

Leng M, Locker D, Giraud-Panis MJ, Schwartz A, Intini FP, Natile G, Pisano C, Boccarelli A, Giordano D & Coluccia M (2000) Replacement of an NH3 by an iminoether in transplatin makes an antitumor drug from an inactive compound. Mol Pharmacol 58, 1525-1535.

Leng M, Schwartz A & Giraud-Panis MJ (2000) Transplatin-modified oligonucleotides as potential antitumor drugs. In Platinum- Based Drugs in Cancer Therapy (Kelland LR & Farrell NP, eds), pp. 63-85. Humana Press Inc, Totowa/NJ.

Brabec V, Sip M & Leng M (1993) DNA conformational distortion produced by site-specific interstrand cross-link of trans-diamminedichloroplatinum(II). Biochemistry 32, 11676-11681.

Brabec V, Reedijk J & Leng M (1992) Sequence-dependent distortions induced in DNA by monofunctional platinum(II) binding. Biochemistry 31, 12397-12402.

Keck MV & Lippard SJ (1992) Unwinding of supercoiled DNA by platinum ethidium and related complexes. J Am Chem Soc 114, 3386-3390.

Brabec V & Leng M (1993) DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues. Proc Natl Acad Sci USA 90, 5345-5349.

Brabec V (2000) Chemistry and structural biology of 1,2-interstrand adducts of cisplatin. In Platinum-based Drugs in Cancer Therapy (Kelland LR & Farrell NP, eds), pp. 37-61. Humana Press Inc, Totowa/NJ.

Kasparkova J, Pospisilova S & Brabec V (2001) Different recognition of DNA modified by antitumor cisplatin and its clinically ineffective trans isomer by tumor suppressor protein p53. J Biol Chem 276, 16064-16069.

Kasparkova J, Fojta M, Farrell N & Brabec V (2004) Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin. Nucleic Acids Res 32, 5546-5552.

Wang D & Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nature Rev Drug Discov 4, 307-320.

Todd RC & Lippard SJ (2009) Inhibition of transcription by platinum antitumor compounds. Metallomics 1, 280-291.

Zhai XQ, Beckmann H, Jantzen HM & Essigmann JM (1998) Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor. Biochemistry 37, 16307-16315.

Kartalou M & Essigmann JM (2001) Recognition of cisplatin adducts by cellular proteins. Mutation Res 478, 1-21.

Damsma GE, Alt A, Brueckner F, Carell T & Cramer P (2007) Mechanism of transcriptional stalling at cisplatin-damaged DNA. Nature Struct Mol Biol 14, 1127-1133.

Danford AJ, Wang D, Wang Q, Tullius TD & Lippard SJ (2005) Platinum anticancer drug damage enforces a particular rotational setting of DNA in nucleosomes. Proc Natl Acad Sci USA 102, 12311-12316.

Ober M & Lippard SJ (2007) Cisplatin damage overrides the predefined rotational setting of positioned nucleosomes. J Am Chem Soc 129, 6278-6286.

Ober M & Lippard SJ (2008) A 1,2-d(GpG) cisplatin intrastrand cross-link influences the rotational and translational setting of DNA in nucleosomes. J Am Chem Soc 130, 2851-2861.

Grivennikov SI & Karin M (2010) Dangerous liaisons: STAT3 and NF-kappa B collaboration and crosstalk in cancer. Cyt Growth Factor Rev 21, 11-19.

Kasparkova J, Farrell N & Brabec V (2000) Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes. J Biol Chem 275, 15789-15798.

Butour JL, Alvinerie P, Souchard JP, Colson P, Houssier C & Johnson NP (1991) Effect of the amine nonleaving group on the structure and stability of DNA complexes with cis-[Pt(R-NH2)2(NO3)2]. Eur J Biochem 202, 975-980.

Taylor BS, de Vera ME, Ganster RW, Wang Q, Shapiro RA, Morris SM, Billiar TR & Geller DA (1998) Multiple NF-κB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J Biol Chem 273, 15148-15156.

Fujita T, Nolan GP, Ghosh S & Baltimore D (1992) Independent modes of transcriptional activation by the p50-subunit and p65-subunit of NF-kappa-B. Genes Dev 6, 775-787.

De Wet JR, Wood KV, Deluca M, Helinski DR & Subramani S (1987) Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 7, 725-737.

Inhibition of nuclear factor kappaB proteins-platinated DNA interactions correlates with cytotoxic effectiveness of the platinum complexes